

# VÃ©ronique Sgambato-Faure

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6603184/publications.pdf>

Version: 2024-02-01

53  
papers

2,943  
citations

218381  
26  
h-index

189595  
50  
g-index

58  
all docs

58  
docs citations

58  
times ranked

3777  
citing authors

#	ARTICLE	IF	CITATIONS
1	Up and Down $\beta$ -Synuclein Transcription in Dopamine Neurons Translates into Changes in Dopamine Neurotransmission and Behavioral Performance in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1807.	1.8	7
2	A metabolic biomarker predicts Parkinson's disease at the early stages in patients and animal models. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
3	Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine. <i>Progress in Brain Research</i> , 2021, 261, 265-285.	0.9	3
4	Selective serotonin reuptake inhibitor treatment retunes emotional valence in primate ventral striatum. <i>Neuropsychopharmacology</i> , 2021, 46, 2073-2082.	2.8	6
5	Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs. <i>Movement Disorders</i> , 2021, 36, 2888-2900.	2.2	37
6	Toxin-Based Rodent Models of Parkinson's. <i>Neuromethods</i> , 2021, , 3-19.	0.2	0
7	Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys. <i>Neurobiology of Disease</i> , 2020, 134, 104643.	2.1	7
8	Blood Flow as a Route for Bidirectional Propagation of Synucleinopathy in Parkinson's Disease?. <i>Movement Disorders</i> , 2020, 35, 1751-1751.	2.2	0
9	Editorial: Non-Dopaminergic Systems in Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2020, 11, 593822.	1.6	15
10	Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?. <i>Frontiers in Neuroscience</i> , 2020, 14, 25.	1.4	30
11	Early limbic microstructural alterations in apathy and depression in de novo Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1644-1654.	2.2	52
12	Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers. <i>Journal of Neural Transmission</i> , 2018, 125, 1145-1156.	1.4	11
13	Historical crossroads in the conceptual delineation of apathy in Parkinson's disease. <i>Brain</i> , 2018, 141, 613-619.	3.7	8
14	Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states. <i>Journal of Neural Transmission</i> , 2018, 125, 485-500.	1.4	15
15	Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey. <i>Movement Disorders</i> , 2018, 33, 298-309.	2.2	9
16	Molecular Imaging of Opioid System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 275-303.	0.9	12
17	Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates. <i>NeuroImage</i> , 2018, 183, 132-141.	2.1	17
18	Ventral Pallidum Encodes Contextual Information and Controls Aversive Behaviors. <i>Cerebral Cortex</i> , 2017, 27, bhw107.	1.6	53

#	ARTICLE	IF	CITATIONS
19	Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. <i>Lancet Neurology</i> , 2017, 16, 238-250.	4.9	280
20	Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update. <i>ACS Chemical Neuroscience</i> , 2017, 8, 973-986.	1.7	37
21	Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 76.	2.0	79
22	Control of the direct pathway by cholinergic interneurons is involved in parkinsonian motor symptoms. <i>Movement Disorders</i> , 2017, 32, 393-393.	2.2	0
23	Characterization and Reliability of [18F]2FNQ1P in Cynomolgus Monkeys as a PET Radiotracer for Serotonin 5-HT <sub>6</sub> Receptors. <i>Frontiers in Pharmacology</i> , 2017, 8, 471.	1.6	10
24	The prominent role of serotonergic degeneration in apathy, anxiety and depression in Parkinson's disease. <i>Brain</i> , 2016, 139, 2486-2502.	3.7	188
25	Cortico-basal ganglia circuits involved in different motivation disorders in non-human primates. <i>Brain Structure and Function</i> , 2016, 221, 345-364.	1.2	27
26	Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms. <i>Journal of Neuroscience</i> , 2016, 36, 1577-1589.	1.7	42
27	Social behavioral changes in MPTP-treated monkey model of Parkinson's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 42.	1.0	17
28	Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT <sub>6</sub> radioligand for PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 495-502.	3.3	17
29	Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate. <i>Brain</i> , 2015, 138, 2632-2647.	3.7	54
30	Selective dysfunction of basal ganglia subterritories: From movement to behavioral disorders. <i>Movement Disorders</i> , 2015, 30, 1155-1170.	2.2	168
31	Serotonergic pharmacology in animal models: From behavioral disorders to dyskinesia. <i>Neuropharmacology</i> , 2014, 81, 15-30.	2.0	33
32	A multi-atlas based method for automated anatomical Macaca fascicularis brain MRI segmentation and PET kinetic extraction. <i>NeuroImage</i> , 2013, 77, 26-43.	2.1	45
33	Towards a primate model of Gilles de la Tourette syndrome: Anatomic-behavioural correlation of disorders induced by striatal dysfunction. <i>Cortex</i> , 2013, 49, 1126-1140.	1.1	77
34	Effects of L-DOPA and STN-HFS dyskinesigenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2012, 48, 379-390.	2.1	15
35	Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. <i>Progress in Neurobiology</i> , 2012, 96, 69-86.	2.8	160
36	Effects of dopamine and serotonin antagonist injections into the striatopallidal complex of asymptomatic MPTP-treated monkeys. <i>Neurobiology of Disease</i> , 2012, 48, 27-39.	2.1	26

#	ARTICLE	IF	CITATIONS
37	Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 84-89.	2.2	112
38	Forelimb dyskinesia mediated by high-frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N-methyl-D-aspartate receptors. <i>European Journal of Neuroscience</i> , 2010, 32, 423-434.	1.2	16
39	Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia. <i>PLoS ONE</i> , 2010, 5, e12322.	1.1	111
40	Primate brain template image and reference atlas creation for voxel-based functional analysis of PET in <i>Macaca fascicularis</i> . <i>NeuroImage</i> , 2010, 52, S174-S175.	2.1	0
41	De novo and long-term L-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat. <i>Neurobiology of Disease</i> , 2009, 34, 340-350.	2.1	25
42	High-Frequency Stimulation of the Subthalamic Nucleus Potentiates L-DOPA-Induced Neurochemical Changes in the Striatum in a Rat Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2007, 27, 2377-2386.	1.7	66
43	The Homer-1 protein Ania-3 interacts with the plasma membrane calcium pump. <i>Biochemical and Biophysical Research Communications</i> , 2006, 343, 630-637.	1.0	57
44	Subthalamic Stimulation-Induced Forelimb Dyskinesias Are Linked to an Increase in Glutamate Levels in the Substantia Nigra Pars Reticulata. <i>Journal of Neuroscience</i> , 2006, 26, 10768-10776.	1.7	96
45	Phosphorylation of DARPP-32 at Threonine-34 is Required for Cocaine Action. <i>Neuropsychopharmacology</i> , 2006, 31, 555-562.	2.8	90
46	Coordinated and Spatial Upregulation of Arc in Striatonigral Neurons Correlates With L-Dopa-Induced Behavioral Sensitization in Dyskinetic Rats. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 936-947.	0.9	85
47	Regulation of ania-6 splice variants by distinct signaling pathways in striatal neurons. <i>Journal of Neurochemistry</i> , 2004, 86, 153-164.	2.1	27
48	Dopamine and Glutamate Induce Distinct Striatal Splice Forms of Ania-6, an RNA Polymerase II-Associated Cyclin. <i>Neuron</i> , 2001, 32, 277-287.	3.8	91
49	Effect of a functional impairment of corticostriatal transmission on cortically evoked expression of c-fos and zif 268 in the rat basal ganglia. <i>Neuroscience</i> , 1999, 93, 1313-1321.	1.1	16
50	Extracellular Signal-Regulated Kinase (ERK) Controls Immediate Early Gene Induction on Corticostriatal Stimulation. <i>Journal of Neuroscience</i> , 1998, 18, 8814-8825.	1.7	308
51	In Vivo Expression and Regulation of Elk-1, a Target of the Extracellular-Regulated Kinase Signaling Pathway, in the Adult Rat Brain. <i>Journal of Neuroscience</i> , 1998, 18, 214-226.	1.7	151
52	EFFECT OF ANGIOTENSIN II ON A SPINAL NOCICEPTIVE REFLEX IN THE RAT: RECEPTOR AND MECHANISM OF ACTION. <i>Life Sciences</i> , 1997, 61, 503-513.	2.0	18
53	Effect of electrical stimulation of the cerebral cortex on the expression of the fos protein in the basal ganglia. <i>Neuroscience</i> , 1997, 81, 93-112.	1.1	100